Revenue increased by 7.4% to $40.5 million in 2025, up from $37.7 million in 2024. Net loss significantly decreased to $17.3 million in 2025, compared to $26.7 million in 2024. Gross profit surged by 85.9% to $13.4 million in 2025, with gross profit percentage improving to 33.2% from 19.2% in 2024 (or 26.5% excluding non-recurring charges). Operating expenses decreased by 8.9% to $30.4 million in 2025, primarily due to lower research and development and general and administrative expenses. Lab Essentials revenue grew by 7.5% to $31.0 million, while Clinical Solutions revenue increased by 7.8% to $7.7 million in 2025. The company entered into a Second Amended and Restated Credit Agreement on March 3, 2025, providing a $28.245 million credit facility, and was in compliance with all financial covenants as of December 31, 2025. A shelf registration statement for up to $225 million in securities was declared effective on July 16, 2025, providing future financing flexibility. A former employee claim was settled for $0.4 million in April 2025.